Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols

Protocols

EDRN investigators protocols. The following is a list of the EDRN protocols that have been captured and curated. Additional information will be added as it is available. Contact information is provided as part of the detail for each protocol.

Contents

Title Abstract Investigator
MALDI Dilution Data: Randolph Feng, Ziding
MMR protein expression in HNPCC Lynch, Henry
MSA Ref Set Applicant: Rosser Rosser, Charles J
Methylation & Proteomics-Based Detection of Bladder Cancer To determine sensitivity and specificity of quantitative real-time methylation specific PCR (qMSP) of urine sediment DNA, using a panel of several methylated ... Cairns, Paul
Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers. BACKGROUND: The transcription factor TCF21 is involved in mesenchymal-to-epithelial differentiation and was shown to be aberrantly hypermethylated in lung and ... Richards, Kristy L.
Methylation tumor markers in HNPCC Lynch, Henry
Molecular Basis of Barrett's -Associated Carcinogenesis Stass, Sanford
Molecular Genetics of Urinary Bladder Carcinoma Czerniak, Bogdan
Molecular Progression of Methylation in Bladder Cancer Sidransky, David
Mutational load distribution analysis (MLDA) in pancreatic cancer Certain p16 mutation carriers showed mutation elevations in the specific Ki-ras and p53 alleles significantly higher than normal, similar to controls with ... Lynch, Henry
NYU Lung Cancer Biomarker Center A. SPECIFIC AIMS 1. To develop and prospectively follow a large cohort at high-risk for lung cancer. Individuals are recruited to one of two different ... Rom, William
National Ovarian Cancer Early Detection Program Blood and Genetics Fishman, David
New Biomarkers & Dysplastic Respiratory Epithelium Franklin, Wilbur Alan
Novel Surveillance Strategies For Hereditary Nonpolyposis Colon Cancer Family Members Lynch, Henry
Ornithine decarboxylase (ODC) Polymorphism and Breast and Prostate Cancer Helzlsouer, Kathy
Ovarian Cancer Screening Pilot Trial In High Risk Women BACKGROUND: No proven ovarian cancer (OC) screening strategy exists for women who are at increased risk for the disease. A risk of ovarian cancer algorithm ... Lynch, Henry
PASS Applicant: Etzioni Etzioni, Ruth
PCA3 Validation Study and Urinary Reference Set Prostate cancer (PCa) is the third leading cause of cancer-related deaths among United States men, accounting for 33% of such diagnosed cancers.(1) An ... Wei, John
PLCO Ovarian Phase III Validation Study The obvious appeal of a strategy for the early detection of ovarian cancer is based upon the tendency for the disease to present at advanced stages associated ... Cramer, Daniel
PTM Microarray: Request for Year 3 Set-Aside Funds We hypothesize that PTMs on proteins that are secreted by the breast will provide a more sensitive method for detecting breast cancer than analysis of the ... Zangar, Richard (Rick) C.
Pancreatic Cancer Early Detection Stem Cell Biomarkers (CA117452 Set-Aside) Lokshin, Anna
Pancreatic Cancer Reference Set Applicant: Honda (2014) Honda, Kazufumi
Pancreatic Cancer Reference Set Applicant: NCI Honda (2014) Honda, Kazufumi
Pancreatic Cystic Fluid Reference Set Brand, Randall E.
Pancreatic Ref Set Applicant: Batra 2014 Batra, Surinder
Pancreatic Ref Set Applicant: Hollingsworth 2014 Hollingsworth, Michael
Pancreatic Reference Set Applicant-Haab (2012) This study will address the clinical problems of early detection and diagnosis. The samples were obtained from patients with early-stage pancreatic cancer, ... Haab, Brian
Pancreatic Reference Set Applicant-Killary (2012) Killary, Ann M.
Pancreatic Reference Set Applicant: Blasutig 2014 Blasutig, Ivan
Panel of serum biomarkers for the diagnosis of lung cancer PURPOSE: Currently, a blood test for lung cancer does not exist. Serum biomarkers that could aid clinicians in making case management decisions would be ... Patz Jr., Edward F.
2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.